eligibility_summary
Eligibility: ECOG 0–1, HLA‑A02:01+, histologically confirmed advanced colorectal, esophageal, gastric, or ovarian cancer, adequate archived/fresh tumor tissue, measurable disease (RECIST 1.1), prior standard therapy, contraception if of childbearing potential. Exclude: symptomatic/untreated CNS mets, recent bowel obstruction, ongoing ascites/effusions needing drainage, significant prior‑tx toxicity, abnormal labs, major lung/heart/autoimmune disease, immunosuppression, secondary malignancy, hypersensitivity, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions: IMC-R117C, a TCR-based bispecific ImmTAC biologic that uses a high‑affinity TCR to bind a PIWIL1-derived peptide presented by HLA‑A02:01 on tumor cells and an anti‑CD3 domain to recruit/activate T cells, redirecting cytotoxic killing (IV). Combinations may include: cytotoxic chemotherapy (DNA/mitotic inhibition), antiangiogenic agent (VEGF/angiogenesis blockade), kinase inhibitor(s) (oncogenic signaling blockade), and monoclonal antibody therapy (targeted receptor/ligand blockade). Targets/cells/pathways: PIWIL1+ HLA‑A02:01 tumor cells (CRC, esophageal, gastric, ovarian), CD3+ T cells via TCR/CD3 engagement, tumor angiogenesis pathways, oncogenic kinase signaling, antibody‑addressed tumor antigens. Control: standard chemotherapy + antiangiogenic agent.